8-K: Silo Pharma Executes 1-for-15 Reverse Stock Split

Silo Pharma, Inc. has filed a Certificate of Change to implement a 1-for-15 reverse stock split, effective June 2, 2026, adjusting its common stock structure and authorized shares.

Summary

• Silo Pharma, Inc. has officially executed a 1-for-15 reverse stock split for its common stock.
• This action became effective on June 2, 2026, at 4:01 p.m. Eastern Time.
• The company's common stock began trading on a split-adjusted basis on June 3, 2026.
• The reverse stock split reduces the number of issued and outstanding shares, with every 15 shares consolidating into one.
• The authorized shares of common stock have been proportionally reduced to 6,666,667.
• Adjustments have been made to outstanding stock options, warrants, and equity incentive plans regarding exercise prices and share numbers.
• Fractional shares resulting from the split will be rounded up to the nearest whole share.
• The stock will continue to trade on The Nasdaq Capital Market under the symbol SILO, with a new CUSIP number assigned.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While a reverse split is a necessary corporate action to maintain exchange listing, it does not inherently improve the company's underlying business performance.

Positives

• The reverse stock split aims to increase the per-share market price of the common stock, potentially making it more attractive to institutional investors and meeting exchange listing requirements.
• Fractional shares are rounded up, which is a shareholder-friendly approach, ensuring no shareholder is left with a fraction of a share without receiving a full share.

Negatives

• A reverse stock split can sometimes be perceived negatively by the market as it often indicates a company's struggle to maintain its stock price.
• The reduction in authorized shares, while necessary for the split, reduces the company's flexibility for future equity issuances without further corporate action.

Risks

• There is a risk that the market may not react favorably to the reverse stock split, potentially leading to continued downward pressure on the stock price.
• The company's ability to meet Nasdaq listing requirements post-split will depend on sustained market performance.

Future Outlook

The filing does not contain specific forward-looking financial guidance. However, the reverse stock split is a structural change intended to improve the stock's marketability and compliance with exchange listing standards.

Management Comments

• The company has filed a Certificate of Change to effectuate a 1-for-15 reverse stock split of its issued and outstanding and authorized shares of common stock.
• The reverse stock split became effective at 4:01 p.m., Eastern Time, on Tuesday, June 2, 2026.
• The company's Common Stock began trading on a split-adjusted basis when The Nasdaq Stock Market opened on June 3, 2026.

Industry Context

StockSavvy.ai notes that reverse stock splits are a common tool for companies, particularly smaller ones listed on exchanges like Nasdaq, to boost their share price and avoid delisting. This action is often taken when a stock price has fallen below minimum thresholds required by the exchange.

Corporate Governance

Stakeholder Impact

• Shareholders will hold fewer shares but each share will represent a larger percentage of ownership, assuming no fractional shares are sold.
• The market price per share is expected to increase proportionally to the split ratio.

Next Steps

• Continue trading on The Nasdaq Capital Market under the symbol SILO on a split-adjusted basis.
• Monitor stock performance to ensure continued compliance with Nasdaq listing requirements.

Key Dates

Recommendation

The reverse stock split is a procedural change aimed at maintaining exchange listing and improving stock marketability, rather than a fundamental business improvement. Investors should hold to assess the company's operational performance and future growth prospects independently of this structural adjustment.

Keywords

reverse stock split, Silo Pharma, common stock, Nasdaq, stock adjustment, Nevada, corporate action, equity